Dual-biomarker strategy for prenatal prediction of ABO hemolytic disease: Maternal sVE-cadherin and anti-A/B IgG titer. [PDF]
Jiang DD, Li JW, Zhang XC.
europepmc +1 more source
The JR blood group system: from discovery to the clinic. [PDF]
Ma X +7 more
europepmc +1 more source
The Ethics of Clinical Research on Diseases of the Fetus and Newborn: Balancing Benefit-Risk, Autonomy, and Maternal-Fetal Interests. [PDF]
Nelson RM +9 more
europepmc +1 more source
Monocyte Monolayer Assay as a Tool in the Early Assessment of the Severity of the Alloantibodies in Patients with Hemolytic Disease of the Fetus and Newborn. [PDF]
Santoro D +10 more
europepmc +1 more source
The THOR network best practices for females of childbearing potential with life-threatening hemorrhage: Guidance for emergency medical services and hospitals. [PDF]
Levy MJ +12 more
europepmc +1 more source
Obstetrical Impact of Anti-MUT (Anti-MNS35) Alloimmunization. [PDF]
Gavillet M +8 more
europepmc +1 more source
Feasibility of Hemolytic Disease of the Fetus and Newborn Case Ascertainment and Assessing Its Impact on Prenatal and Postnatal Outcomes: Protocol for Observational Studies. [PDF]
Mensah NA +12 more
europepmc +1 more source
Hemolytic disease of the newborn heralds hemorrhagic disease of the newborn. [PDF]
Mir YA +4 more
europepmc +1 more source
Anti-Kp<sup>a</sup> antibody: Getting to know a strange and dangerous specificity. [PDF]
Santacruz MQ.
europepmc +1 more source

